Tag: atossa genetics

March 14, 2019

Atossa Genetics Soars on FDA Expanded Access Program Approval

Shares of Atossa Genetics were up over 368 percent on Thursday to close at US$7.07 following the approval from the...
October 26, 2017

Atossa Genetics Prices Public Offering of Common Stock

Atossa Genetics shared the pricing of an underwritten public offering of 11,500,000 shares of common stock.
July 25, 2017

Atossa Genetics Completes Enrollment in Endoxifen Phase 1 Study

Atossa Genetics completed enrollment for their Phase 1 dose escalation study of Atossa's proprietary Endoxifen.
June 26, 2017

Atossa Genetics Gets Interim Safety Data from Ongoing Study

Atossa Genetics shared a batch of positive interim safety data from its Phase 1 dose escalation study on Endoxifen.
May 19, 2017

Atossa Genetics Completes Enrollment for Trial

Atossa Genetics announced it completed enrollment for a Phase 1 study of Endoxifen.
September 14, 2016

Atossa Genetics Regains Compliance With NASDAQ Listing Requirement

NASDAQ today notified Atossa Genetics that the company was once more compliant with NASDAQ's minimum closing bid price listing rule...
May 1, 2016

5 Top NASDAQ Biotech Stocks: Atossa Genetics and BioTelemetry Top Gainers

StemCells, Biostage and ARCA biopharma round off top five gainers.